CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net loss	$ (2,112,000)	$ (1,882,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation	1,012,000	950,000
Amortization	1,374,000	1,633,000
Stock based compensation expense	532,000	225,000
Loss on debt extinguishment		318,000
Change in fair value of warrant liability	(706,000)	491,000
Changes in operating assets and liabilities:
Accounts receivable	48,000	(1,908,000)
Inventories	1,181,000	(1,119,000)
Prepaid expenses and other assets	41,000	(323,000)
Accounts payable	(1,226,000)	1,092,000
Accrued expenses	(14,000)	50,000
Net cash provided by (used in) operating activities	130,000	(473,000)
Cash flows from investing activities:
Capital expenditures	(583,000)	(1,396,000)
Change in restricted cash	500,000
Patent expenditures	(199,000)	(251,000)
Net cash used in investing activities	(282,000)	(1,647,000)
Cash flows from financing activities:
Payments on bank term loan	(1,685,000)	(434,000)
Payments on bank line of credit	(494,000)	(900,000)
Proceeds from bank term loan	1,998,000
Proceeds from bank line of credit	500,000
Payments on MEDC/MSF term loan	(510,000)	(253,000)
Payments on related party debt	(1,175,000)	(226,000)
Net proceeds from sale of class A common stock		6,567,000
Proceeds from exercise of warrants		243,000
Proceeds from exercise of stock options	23,000	105,000
Net cash provided by (used in) financing activities	(1,343,000)	5,102,000
Net increase (decrease) in cash and cash equivalents	(1,495,000)	2,982,000
Cash and cash equivalents, beginning of year	4,744,000	1,762,000
Cash and cash equivalents, end of year	3,249,000	4,744,000
Supplemental cash flow information:
Cash paid for interest	174,000	256,000
Cash paid for income taxes